A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Inclusion Criteria:

* Age 18 years or older
* Performance status 2 or less
* Ovarian cancer, high grade serous or high grade endometrioid histology subtype
* Radiographically documented disease progression per RECIST 1.1
* Progression on olaparib therapy after an initial good response (more than 6 months)
* Patients must have adequate bone marrow, renal and hepatic function per local laboratory reference range
* Ongoing prior toxicities related to previous treatments recovered to grade 2 or less
* LVEF\>50% by echocardiograms or MUGA
* Urine dipstick for proteinuria \<2+
* Willing to undergo tumour biopsy pre-treatment
* Life expectancy of greater than 3 months
* Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

* Current bowel obstruction
* Known brain metastases
* Mean QTc \>470 msec (with Bazett's correction) in screening ECG or history of familial long QT syndrome.
* Uncontrolled intercurrent illness including, but not limited to hypertension, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* A New York Heart Association classification of III or IV requiring concurrent use of drugs or biologics with proarrhythmic potential.
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to olaparib or cediranib
* Unable to swallow orally administered medication and/or gastrointestinal disorders likely to interfere with absorption of the study medication.
* Myelodysplastic syndrome/acute myeloid leukaemia
* Immuno-compromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV), patients with known active hepatitis (i.e.,hepatitis B or C) due to risk of transmitting the infection through blood or other body fluids.